{"name":"CTI-1, LLC","slug":"cti-1-llc","ticker":"","exchange":"","domain":"","description":"CTI-1, LLC is a specialty pharmaceutical company focused on the development and commercialization of innovative treatments for cardiovascular diseases. The company's lead product is in Phase 3 clinical trials, aiming to address significant unmet medical needs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"carvedilol immediate release","genericName":"carvedilol immediate release","slug":"carvedilol-immediate-release","indication":"Hypertension","status":"phase_3"}]}],"pipeline":[{"name":"carvedilol immediate release","genericName":"carvedilol immediate release","slug":"carvedilol-immediate-release","phase":"phase_3","mechanism":"Carvedilol immediate release is a beta-blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline, and by slowing the heart rate and reducing its workload.","indications":["Hypertension","Heart failure"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-26","type":"earnings","source":"simplywall.st","summary":"There May Be Reason For Hope In MIND C.T.I's (NASDAQ:MNDO) Disappointing Earnings - simplywall.st","headline":"There May Be Reason For Hope In MIND C.T.I's (NASDAQ:MNDO) Disappointing Earnings","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}